DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger

IntroductionFluoropyrimidines (FP) are the mainstay of colorectal cancer (CRC) treatment, but can cause severe toxicity in up to 40% of patients. Variants in the DPYD gene are associated with these adverse events. A DPYD-guide dose adjustment is now recommended in Europe. This ambispective study aim...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Rocío Rosas-Alonso, Nuria Rodríguez Salas, Pablo Perez Wert, Angela Hoyo, Susana Martin-López, Daniel Martínez-Pérez, Iciar Ruiz-Gutiérrez, Diego Jiménez-Bou, Jesús Peña, Pedro Arias, Ana Custodio, Itsaso Losantos-García, Alberto M. Borobia, Jaime Feliu, Ismael Ghanem
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-09-01
Subjects:	fluoropyrimidines DPYD colorectal cancer toxicity discontinuation
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1645188/full